Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.

@article{Kim2011LuteolinAN,
  title={Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.},
  author={Jong-Eun Kim and Joe Eun Son and Young Jin Jang and Dong Eun Lee and Nam Joo Kang and Sung Keun Jung and Y Heo and Ki Won Lee and Hyong Joo Lee},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2011},
  volume={338 3},
  pages={1013-22}
}
Targeting tumor necrosis factor (TNF)-α-mediated signal pathways may be a promising strategy for developing chemopreventive agents, because TNF-α-mediated cyclooxygenase (COX)-2 expression plays a key role in inflammation and carcinogenesis. Luteolin [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone] exerts anticarcinogenic effects, although little is known about the underlying molecular mechanisms and specific targets of this compound. In the present study, we found that luteolin inhibited… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2008
View 2 Excerpts

Similar Papers

Loading similar papers…